Takeda’s/Sucampo Amitiza Gains IBS-C Indication
This article was originally published in PharmAsia News
Takeda/Sucampo Pharmaceuticals' chronic idiopathic constipation drug Amitiza (lubiprostone) was approved by FDA April 29 for irritable bowel syndrome with constipation in women 18 years and older, making it the only drug available for IBS-C with a prescription
You may also be interested in...
TOKYO - Sucampo's chronic idiopathic constipation treatment Amitiza (lubiprostone) may soon have a chance at a second life in a new market after the company announced positive results of a pivotal Phase III trial in Japanese patients
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).